Engflag

Gibtulio

Quick links to important sections

Gibtulio

Gibtulio_EN

Treatment option:

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Gibtulio

What is Gibtulio? An Overview

Property Description
Active ingredient Empagliflozin
Form Film-coated tablet
Pharmacological class Sodium-Glucose Co-Transporter 2 (SGLT2) Inhibitor
Common use Improvement of glycemic control in Type 2 diabetes mellitus
Origin Synthetic organic C-glycoside analog

Defining the Core Drug Entity and Active Component

Gibtulio is a synthetic, prescription-only anti-diabetic agent intended for oral administration, formally classified as a Sodium-Glucose Co-Transporter 2 (SGLT2) Inhibitor. The medicine is defined by its sole active component, Empagliflozin, which is available as a film-coated tablet. Empagliflozin is structurally recognized as a C-glycoside analog, a chemical feature that gives it greater stability compared to older sugar-based compounds. This SGLT2 Inhibitor class is clinically recognized for providing a unique, insulin-independent mechanism for managing high blood sugar.

The Principle of Action and General Therapeutic Purpose

The overall purpose of Gibtulio is to improve glycemic control by directly influencing the kidney's function in handling glucose. The drug works by selectively blocking the SGLT2 protein located in the renal tubules, which is normally responsible for reabsorbing the majority of filtered glucose back into the bloodstream. By inhibiting this protein, Gibtulio causes sugar to be passed out of the body through the urine, a process known as glucuresis.

This distinct physiological action is supported by pharmacological studies demonstrating its reliable effect on lowering plasma glucose concentrations. For an adult patient with Type 2 diabetes mellitus, the general therapeutic purpose of Gibtulio is to consistently reduce high blood sugar levels, which is fundamental to long-term metabolic health management.

Regulatory References

  1. SGLT2 Inhibitors Mechanism of Action

What side effects are possible with Gibtulio?

Adverse Reaction Scope

Adverse reactions associated with Gibtulio (empagliflozin) are officially categorized by system and frequency. In clinical trials, the most frequent adverse reactions (classified as Common or Very Common) relate to the Infections and Infestations system, including urinary tract infections and genital mycotic infections (such as vaginal yeast infection or balanitis).

Reactions classified as Very Common (ge 1/10) include low blood sugar (hypoglycemia) when used in combination with insulin or a sulfonylurea, and adverse events related to volume depletion (reduced body fluids).

Serious Adverse Reactions and System-Organ Classes

The official label highlights certain rare but clinically significant conditions: Diabetic Ketoacidosis (DKA), which may present atypically with lower-than-expected blood glucose levels; Necrotizing Fasciitis of the Perineum (Fournier's Gangrene), a rare, serious infection; and severe complicated UTIs, such as urosepsis and pyelonephritis. These, along with volume depletion-related reactions like hypotension and Acute Kidney Injury, fall under the Metabolism, Infections, Vascular, and Renal System-Organ Classes.

Population-Specific Safety Constraints

The safety profile includes specific constraints for certain populations. The medication is contraindicated in individuals with severe renal impairment, end-stage renal disease, or on dialysis. Older adults (especially those aged 75 years and older) may have a higher incidence of volume depletion-related events. Increased risk of hypoglycemia is noted for pediatric patients (aged 10 and older), regardless of insulin use. Furthermore, the label specifies conditions under which temporary discontinuation should be considered, such as prior to major surgery or during acute severe illness, as these situations may predispose to ketoacidosis.

Overdose and Emergency Response

Overdose and When to Seek Help

Official regulatory documentation structures the Gibtulio (empagliflozin) overdose profile around the risk of severe metabolic and hemodynamic complications. Taking more than the prescribed amount may lead to manifestations consistent with severe metabolic acidosis or Diabetic Ketoacidosis (DKA), which is classified as a serious, life-threatening condition requiring urgent medical intervention.

Documented clinical presentations of overdose or severe exposure include gastrointestinal symptoms such as nausea, vomiting, and abdominal pain, alongside signs of systemic distress like unusual tiredness, confusion, or difficulty breathing. The risk of volume depletion is also a key factor, potentially resulting in symptomatic hypotension (low blood pressure) and dizziness. Geriatric patients are noted in official labeling to have a higher incidence of adverse effects related to volume depletion and reduced kidney function.

In the event that an overdose is suspected, or if symptoms of ketoacidosis or a serious allergic reaction (such as swelling of the face or throat) appear, the individual must seek medical attention immediately and discontinue the medication. Treatment for overdose is officially described as symptomatic and supportive care. While there is no specific antidote known for empagliflozin, prompt medical management, including fluid and carbohydrate replacement, is required for complications like DKA.

Therapeutic Uses of Gibtulio

Gibtulio: Targeted Symptom Management and Supportive Relief

Gibtulio (containing empagliflozin) is applied across domains where additional symptomatic support is needed, primarily for conditions involving type 2 diabetes mellitus. Its core therapeutic domain is focused on areas where additional symptomatic support is needed, which may include conditions associated with systemic or localized discomfort. It is used in scenarios that involve symptoms related to systemic imbalance, functional strain, and episodic symptom patterns.

Easing Periods of Heightened Discomfort and Symptom Intensity

This medication is relevant for easing symptoms related to systemic imbalance, by supporting the management of the underlying condition that creates systemic imbalance. It contributes to easing the overall symptom load, which may assist with maintaining a sense of day-to-day functional stability.

Quick Fact: Supports Systemic Discomfort

Supporting Comfort Through Episodic or Fluctuating Symptom Patterns

Gibtulio is commonly used across conditions characterized by periods of heightened symptoms, such as the fluctuations seen in chronic kidney disease and heart failure management. It provides supportive relief that helps with coping during periods marked by acute or disruptive manifestations, and contributes to improved comfort during symptomatic periods.

Temporary Assistance for Functional Strain and Disruption

Applied in clinical settings that involve acute or unstable symptom patterns, Gibtulio plays a role in managing symptoms that create noticeable functional strain or interfere with daily functioning. It offers symptomatic relief and helps patients cope more steadily with symptom fluctuations, thereby supporting general well-being by helping to maintain a sense of functional stability.

Eligibility and Restrictions for Use

Groups Permitted for Use

Gibtulio (empagliflozin) is primarily approved for use in adults with Type 2 Diabetes Mellitus (T2DM). The use for glycemic control is also extended to pediatric patients aged 10 years and older with T2DM. Adults are also eligible for use in specific cardiorenal conditions.

Official Contraindications and Restrictions

Use of Gibtulio is contraindicated and prohibited for certain populations, as mandated by regulatory bodies:

  • Hypersensitivity: Patients with a history of a serious hypersensitivity reaction to Empagliflozin or any excipient in the product must not use this medicine.
  • Severe Renal Impairment: The medicine is contraindicated in patients with severe renal impairment (eGFR < 30 mL/min/1.73 m^2), End-Stage Renal Disease (ESRD), or those on dialysis.
  • Type 1 Diabetes Mellitus (T1DM): Gibtulio is not recommended for improving glycemic control in patients with T1DM.
Population/Condition Eligibility Status
Pregnancy (2nd/3rd Trimesters) Not Recommended
Lactation/Breastfeeding Not Recommended
Children Younger than 10 Use Not Established
Severe Hepatic Impairment Not Recommended

The official eligibility profile limits use based on disease type and critically depends on the patient's renal function status. Use is also restricted based on reproductive status.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Gibtulio (empagliflozin) has documented interaction patterns primarily focused on pharmacodynamic effects and the drug’s clearance pathways, as described in regulatory labels.

Pharmacodynamic Interactions

Co-administration with Diuretics (Thiazide or Loop) is officially noted to increase the potential for symptomatic hypotension and volume depletion due to the combined, additive effects on fluid and sodium excretion. Similarly, the simultaneous use of Insulin or Insulin Secretagogues (such as Sulfonylureas) is documented to increase the risk of hypoglycemia as a result of the combined glucose-lowering actions. Empagliflozin’s effect on excretion may also lead to a decrease in serum Lithium levels. Specific regulatory caution is noted for elderly patients and those with renal impairment, as these populations face an increased risk of volume depletion-related adverse reactions when Gibtulio is combined with diuretics or certain blood pressure medicines, like ACE inhibitors or ARBs.

Pharmacokinetic and Substance Interactions

Empagliflozin is cleared primarily via glucuronidation. Co-administration with strong UGT enzyme inducers, such as rifampicin, is officially documented to reduce Empagliflozin plasma concentration (exposure). While Empagliflozin is a substrate for P-glycoprotein (P-gp) and BCRP transporters, interactions involving most inhibitors of these transporters are not considered clinically significant. Separately, consumption of alcohol is a documented substance interaction that may increase the risk of hypoglycemia and is an established risk factor for diabetic ketoacidosis. The administration of Gibtulio is not restricted by food intake, as a high-fat meal does not result in a clinically significant change in drug exposure.

Mechanism of Action

Gibtulio functions as a small-molecule inhibitor targeting the enzyme Farnesyl Pyrophosphate Synthase (FPPS). FPPS is an essential component of the mevalonate pathway, responsible for catalyzing the formation of farnesyl diphosphate (FPP). Gibtulio achieves its action by competitively binding to the active site of FPPS, thereby preventing the synthesis of FPP.

The resulting reduction in intracellular FPP concentration leads to the impaired farnesylation of key regulatory proteins, specifically small G proteins (GTPases) such as Rho, Ras, and Rac. These GTPases require a farnesyl group derived from FPP for proper membrane localization and activation. The disruption of membrane anchoring impairs multiple downstream intracellular signaling cascades, including the MAPK and PI3K/AKT pathways.

At the cellular level, this perturbation of signaling primarily affects osteoclasts—the cells responsible for bone resorption—by inhibiting their function and viability. This action results in a system-level modulation of bone metabolism without directly influencing the activity of osteoblasts (bone-forming cells).

Dosage and Administration Information

Official Administration Guidelines for Gibtulio (Empagliflozin)

These instructions outline the official use of Gibtulio (Empagliflozin) as specified in official documentation.

Route and Frequency

Gibtulio is administered orally as a film-coated tablet. The medicine should be taken once daily in the morning, with or without food. Combination products, such as those containing empagliflozin and metformin, may require twice-daily dosing with meals.

Dosing Schedules

The recommended starting dose for adults is 10 mg once daily. The dose may be increased to a maximum of 25 mg once daily in patients who tolerate the 10 mg dose and require additional control. For non-glycemic indications (e.g., heart failure), the recommended dose is typically 10 mg once daily.

Administration Rules

  • Tablet Handling: Tablets should be swallowed whole with water. Do not crush, split, or chew the tablets, particularly combination extended-release formulations.
  • Missed Dose: If a dose is missed, take it as soon as it is remembered. However, do not take a double dose on the same day to make up for the missed one.

Population and Procedural Instructions

  • Kidney Function: Assessment of kidney function (eGFR) is recommended prior to initiation. Use for glycemic control is generally not recommended when the eGFR is below 30 mL/min/1.73 m². The dose may be limited to 10 mg daily in patients with specific ranges of reduced kidney function.
  • Volume Status: Correction of any volume depletion (dehydration) is recommended before starting therapy.
  • Fasting/Surgery: The medicine should be withheld for at least three days, if possible, before major surgery or procedures that involve prolonged fasting.

Recent Clinical Evidence

Research Exploring Type 2 Diabetes Mellitus (T2DM)

Research was studied for use in adults who have Type 2 Diabetes Mellitus. These studies primarily involve Randomized Controlled Trials (RCTs), where patients were randomly assigned to receive Gibtulio or a comparison treatment, such as a placebo. The main purpose of these studies was to explore outcomes related to key biomarkers for blood sugar control, such as Glycated Hemoglobin (HbA1c). Studies monitored HbA1c changes and other measurements, including fasting blood sugar and body weight, over the short-term study duration.

Research Exploring Cardiovascular Outcomes

Specific research was evaluated in large, long-term clinical trials known as Cardiovascular Outcome Trials (CVOTs). These studies included patients with T2DM who also had established heart and blood vessel disease. The trials monitored the time to first occurrence of the composite MACE outcome (cardiovascular death, nonfatal heart attack, or nonfatal stroke) and Hospitalization for Heart Failure (HHF).

Research Exploring Chronic Heart Failure

Dedicated studies were evaluated in populations with chronic heart failure across the entire range of heart function, including both reduced (HFrEF) and preserved (HFpEF) pumping ability. These studies monitored the time to first occurrence of the composite cardiovascular death or HHF outcome in the study groups. Evidence was found to be consistent whether or not patients also had Type 2 Diabetes.

Research Exploring Chronic Kidney Disease Progression

Research was evaluated in large, long-term trials focusing on outcomes related to kidney health in a broad population of patients with Chronic Kidney Disease (CKD), with and without T2DM. The trials monitored the time to first occurrence of the composite renal disease progression endpoint (e.g., need for dialysis or kidney transplant). Studies describe patterns related to the average eGFR slope (rate of kidney function decline) observed in the populations.

Frequently Asked Questions (FAQ)

Common questions about Gibtulio (FAQ)

Q: Does Gibtulio make you feel tired or dizzy?

A: According to regulatory documents, dizziness is listed as a common adverse reaction associated with this medicine. If dizziness or any other concerning symptoms are experienced, it is generally advised to report them to a healthcare provider.

Q: How long does it typically take for Gibtulio to start working?

A: Official information describes that the medicine is absorbed relatively quickly, reaching its highest level in the bloodstream within a few hours of the first dose. The drug's stable concentration in the body, known as steady-state, is generally observed after approximately six days of continuous use.

Q: Are there any dietary restrictions while taking Gibtulio?

A: Official guidance states that Gibtulio can be taken with or without food. Taking it alongside a meal does not affect how the body absorbs the medicine or how it works.

Q: Does Gibtulio interact with common pain relievers like ibuprofen?

A: Based on some official health guidance, the medicine is described as having no significant interaction with common, everyday pain relievers such as ibuprofen. However, information about all medicines and pain relievers should be shared with a healthcare provider.

Q: Are there any known interactions between Gibtulio and birth control pills?

A: Clinical studies cited in regulatory documents found that this medicine did not show a clinically relevant interaction with common oral contraceptives. This means that its use is not expected to significantly alter the levels of birth control pills in the body.

Q: Is Gibtulio safe to take with my vitamins and supplements?

A: Official product information notes there is limited specific data regarding interactions with most vitamins and supplements. However, it is important to inform a healthcare professional about all concomitant products, as some can affect blood sugar levels and may need monitoring.

Q: Does Gibtulio affect my ability to drive or operate machinery?

A: The medicine is described as having no or negligible influence on the ability to drive or operate heavy machinery. However, if Gibtulio is used in combination with other blood sugar-lowering medicines, the risk of low blood sugar (hypoglycemia) may be increased, which could affect concentration and coordination.

Q: What does the official safety information say about long-term use?

A: Long-term use of the medicine has been assessed in large-scale clinical trials, such as cardiovascular outcome trials. These studies, which monitored patients for periods of two to four years, help provide official safety data for continuous use.

Q: Can men and women use Gibtulio for the same conditions?

A: Regulatory documentation indicates that Gibtulio is approved for use in both adult men and women for its official indications. This includes conditions such as Type 2 diabetes and specific heart conditions.

Q: Can Gibtulio interact with herbal teas?

A: Official health guidance mentions that there is limited specific interaction data for herbal teas and this medicine. It is generally recommended to share information about any herbal products used with a healthcare provider, as some may have an effect on blood sugar levels and the overall treatment.

Q: How do I know if the Gibtulio I have is expired?

A: The expiration date is always clearly printed on the container label or packaging by the manufacturer. Regulatory guidance specifies that the medicine should not be used past this date.

Q: Does Gibtulio affect the liver?

A: The official safety information notes that the medicine is not recommended for use in patients who have severe hepatic impairment. This means that severe liver issues can restrict a person’s eligibility to use this medicine.

Q: Is it described that Gibtulio has an effect on sleep?

A: Clinical trials have reported that sleep-related disorders, such as insomnia (difficulty sleeping), have occurred as adverse reactions. Any changes in sleep patterns should be reported to a healthcare provider.

Q: Can I take Gibtulio if I am lactose intolerant?

A: Official product information confirms that the film-coated tablets contain an inactive ingredient known as lactose monohydrate. If a person has a sensitivity to lactose, they may wish to discuss this component with a healthcare professional.

Q: Is there a risk of weight change when taking Gibtulio?

A: Studies have examined the effect of this medicine on body weight in patients with Type 2 diabetes. The evidence describes that its use has been associated with a reduction in body weight in these patient groups.

Q: What did the main clinical trials for Gibtulio show?

A: Clinical trial data indicate two key outcomes. First, the medicine showed improvement in measures of blood sugar control. Second, in specific patient populations, evidence described a reduction in the risk of cardiovascular death and hospitalization for heart failure.

Q: What does 'contraindication' mean in the context of Gibtulio's use?

A: A contraindication is a concept described in official medical documents that refers to a specific condition or circumstance where the medicine is formally prohibited from use. In such cases, the risk of harm outweighs any potential benefit, and use is not permitted.

Q: Why is it described that Gibtulio is sometimes used with other medications?

A: Regulatory indications state that the medicine is approved to be used either as a single treatment (monotherapy) or as add-on combination therapy with other drugs. This is done to achieve comprehensive control of blood sugar levels or to address related cardiorenal conditions.

Q: What is the difference between a side effect and a serious adverse reaction for Gibtulio?

A: Official documents categorize adverse reactions based on their nature and frequency. While many are common side effects, certain rare but clinically significant conditions are officially identified as Serious Adverse Reactions, such as diabetic ketoacidosis or necrotizing fasciitis.

Q: What are the main benefits of Gibtulio, according to the official label?

A: The official label indicates that the medicine is used to improve glycemic control (blood sugar management) in adults with Type 2 diabetes. Additionally, it is approved to reduce the risk of specific major outcomes, including cardiovascular death and hospitalization for heart failure, in certain eligible patients.

Q: Is Gibtulio safe for people with kidney issues?

A: Official documents state that the medicine is officially contraindicated (not permitted) for people with severe kidney impairment or who are on dialysis. For people with less severe kidney issues, initial assessment and ongoing monitoring of kidney function are officially required, and official guidance states that the dose may be limited.

Q: Does Gibtulio have a long-term effect or do I need to keep taking it?

A: The medicine is described as a continuous, once-daily treatment to maintain its effects over time. Treatment interruptions are generally only necessary for specific medical events, such as before major surgery or during an acute severe illness.

How should Gibtulio be stored and disposed of?

How to Store and Dispose of Gibtulio (Empagliflozin)

Gibtulio tablets must be stored according to specific regulatory requirements to maintain product stability and ensure safety.

Storage Requirements

  • Temperature: Store the tablets at controlled room temperature, specifically between 20 C and 25 C (68 F and 77 F). Temporary excursions outside of this range are permitted, up to 30 C (86 F).
  • Container: The medicine must be kept in the original container and sealed tightly closed to protect it from excess heat and moisture.
  • Safety: The product must be stored out of the sight and reach of children at all times.

Disposal Instructions

Unused or expired Gibtulio should be disposed of through a dedicated drug take-back program when available. If a take-back program is not accessible, the medication should be mixed with an undesirable substance, such as dirt or used coffee grounds, sealed in a bag or container, and placed in the household trash. The tablets must not be disposed of by flushing them down a toilet or pouring them down a drain.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Gibtulio found in:

A-Z Index: